Assesment of P wave duration and dispersion in Parkinson's disease

Abstract

Cardiovascular disorders such as decreased heart rate variability, orthostatic hypotension, and arrhythmias have been frequently observed in Parkinson's disease (PD) patients. In this study, authors measured P wave duration and dispersion in PD patients and controls. Twenty-three consecutive patients with idiopathic PD and sex–age matched 23 control subjects were included to the study. A 12-lead surface ECG was obtained from each participant. Maximum–minimum P wave duration and P wave dispersion (PWD) were measured in both groups. Maximum P wave duration was found to be higher in PD patients than controls (117 ± 12 vs. 105 ± 9 ms p = 0.001). Minimum P wave duration was similar in PD patients and controls (64 ± 11 vs. 63 ± 11 ms p = 0.7). PWD in PD patients was also found to be higher than those of controls (53 ± 11 vs. 43 ± 10 ms p = 0.0001). P wave duration and PWD did not significantly differ between PD patients taking anti-parkinsonian agents from those who were not (119 ± 13 vs. 116 ± 13 ms p = 0.4 and 55 ± 11 vs. 52 ± 11 ms p = 0.5, respectively). Moreover, when the PD patients taking anti-parkinsonian agents were excluded from the study, PD patients had still higher P wave duration and PWD compared to controls (119 ± 11 vs. 105 ± 9 ms p = 0.004, 52 ± 10 vs. 43 ± 10 ms p = 0.009, respectively). In conclusion, we found that P wave duration and PWD were greater in PD patients compared to control subjects.